Premium
Effects of garlic powder supplementation on metabolic syndrome components, insulin resistance, fatty liver index, and appetite in subjects with metabolic syndrome: A randomized clinical trial
Author(s) -
Sangouni Abbas Ali,
Alizadeh Mohammad,
Jamalzehi Atena,
Parastouei Karim
Publication year - 2021
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.7146
Subject(s) - medicine , insulin resistance , endocrinology , metabolic syndrome , appetite , blood pressure , triglyceride , homeostatic model assessment , insulin , fatty liver , obesity , cholesterol , disease
The prevalence of metabolic syndrome (MetS) is increasing. It is closely linked to nonalcoholic fatty liver disease. Garlic consumption as a strategy for the management of MetS has been suggested. We investigated the effect of garlic supplementation on MetS components, insulin resistance, fatty liver index (FLI), and appetite in subjects with MetS. Ninety subjects were assigned to receive 1,600 mg/d garlic powder or placebo for 3 months. The primary outcomes included MetS components. The secondary outcomes included insulin resistance, FLI, and appetite. Garlic supplementation compared with the placebo led to a significant increase in high density lipoprotein‐cholesterol (4.5 vs. −1.8, p < .001) and a significant reduction in waist circumference (−1.3 vs. 0.0, p = .001), diastolic blood pressure (−6.7 vs. 0.0, p < .001), systolic blood pressure (−7.7 vs. 0.5, p < .001), triglyceride (−40.0 vs. 0.1, p < .001), γ‐glutamyl transferase (−3.2 vs. 0.6, p = .01), FLI (−5.5 vs. 0.1, p < .001), insulin (−2.9 vs. −1.1, p < .001), homeostatic model of assessment for insulin resistance (−0.5 vs. −0.3, p < .001) and appetite (hunger: −11.7 vs. 1.7, p < .001; fullness: 10.0 vs. 0.3, p = .001; desire to eat: −6.7 vs. 2.1, p < .001; and ability to eat: −11.5 vs. −1.0, p < .001). Garlic improves MetS components, insulin resistance, FLI, and appetite.